rna-editing
(3)
Todd Bazemore
Todd Bazemore is the President and CEO of AIRNA, a Cambridge, Massachusetts biotech developing RNA-editing medicines that rewrite disease-causing genetic variants without permanently altering DNA. Appointed in June 2026, he arrived as the company's lead program, AIR-001 for alpha-1 antitrypsin deficiency, moved into the clinic on the back of an oversubscribed $155 million Series B. A University of Massachusetts Lowell graduate with more than 30 years in rare-disease drug development, he previously ran Kala Bio, led U.S. operations at Santhera, and was chief commercial officer at Dyax during its $6.5 billion acquisition by Shire.
Jacob Borrajo
Jacob Borrajo is the Founder and CEO of Amber Bio, a Cambridge-based biotech company pioneering a first-of-its-kind RNA writing platform capable of multi-kilobase edits. With a PhD in Biological Engineering from MIT and research training at the Broad Institute, Borrajo has spent his career building at the intersection of CRISPR, machine learning, and synthetic biology. Amber Bio launched in August 2023 with a $26 million seed round co-led by Andreessen Horowitz and Playground Global, with strategic participation from Eli Lilly and the Retinal Degeneration Fund. His platform's key innovation: treating diseases with high allelic diversity using a single therapeutic product, by editing RNA rather than DNA - making gene therapy safer, reversible, and dramatically more scalable.
Nessan Bermingham
Nessan Bermingham, Ph.D., is a serial biotech entrepreneur and Operating Partner at Khosla Ventures who has co-founded eight biotechnology companies including Intellia Therapeutics - one of the first public CRISPR gene editing companies - which he built from concept to IPO in under two years. A child of an Irish Army officer raised on a military base in Co. Kildare, he traded academia for Wall Street, Wall Street for venture capital, and venture capital for founding the companies reshaping genetic medicine. Today he shepherds a portfolio of cutting-edge biotech companies at Khosla Ventures while pursuing 155-mile ultra-marathons and aspiring to race at Dakar.